Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05082025
Title Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

endometrial cancer

ovarian cancer

breast cancer

Advanced Solid Tumor

Therapies

Copanlisib + Fulvestrant

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST